News Quantified

ONCT – oncternal therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.

3.7%

MISS

-3.3%

MISS

-7.3%

BEAT

4.4%

IN-LINE

Form ARS Oncternal Therapeutics, For: Dec 31

Form DEFA14A Oncternal Therapeutics,

Form DEF 14A Oncternal Therapeutics, For: Jun 20

Form 4 Oncternal Therapeutics, For: Apr 08 Filed by: Wills Robert James

Form 4 Oncternal Therapeutics, For: Mar 28 Filed by: Wills Robert James

Top News Gainers

6/10 Oncternal Therapeutics Completes Reverse Merger with GTx, Inc. 61.2%

10/11 Oncternal Should Be On Your Radar As Speculative Play Based On Recent Progress [Seeking Alpha] 31.5%

3/11 Oncternal Therapeutics Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma 12.2%

8/11 Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 11.1%

11/5 Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting 8.8%

6/18 Form SC 13D Oncternal Therapeutics, Filed by: Shanghai Pharmaceutical (USA) Inc. 7.9%

12/23 Form 8-K Oncternal Therapeutics, For: Dec 23 7.5%

8/6 Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib 5.7%

11/11 Oncternal Therapeutics to Present at Stifel Healthcare Conference 5.7%

9/9 Form 4 Oncternal Therapeutics, For: Sep 05 Filed by: Kaufmann Gunnar F. 3.9%

Top News Decliners

3/11 Oncternal Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update -16.2%

6/11 Form 3 GTX INC /DE/ For: Jun 07 Filed by: HALE DAVID F -16.2%

8/9 Form 8-K/A Oncternal Therapeutics, For: Jun 07 -12.6%

12/9 Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual Meeting -11.8%

4/2 Form 8-K Oncternal Therapeutics, For: Apr 02 -11.7%

3/18 Form 4 Oncternal Therapeutics, For: Mar 17 Filed by: VINCENT RICHARD G -10.8%

12/11 Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma -10.6%

8/15 Form S-8 Oncternal Therapeutics, -9.8%

6/20 Form 4 Oncternal Therapeutics, For: Jun 18 Filed by: BREITMEYER JAMES B -9.2%

12/12 Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in Combination with Paclitaxel at 2019 San Antonio Breast Cancer Symposium -9.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day